2015


To access this material please log in or register

Register Authorize
2015/№5

Efficacy of original perindopril in patients with arterial hypertension: results of the “PRIZNANIE” regional program

Filippov E. V.
State Budgetary Educational Institution, “Ryazan State Medical University” of the RF Ministry of Healthcare, Vysokovoltnaya 9, Ryazan 390026

Keywords: perindopril, hyperpiesis, treatment, epidemiology

DOI: 10.18087 / rhj.2015.5.2129

Background. Results of the MERIDIAN-RO study showed that patients with AH often receive ACEIs (29.6 %) and 50 % of them are generics. Aim. To evaluate the effect of additional BP reduction after switching patients with AH of different severity from perindopril generics to the original drug, Prestarium A. Materials and methods. The study was designed as a prospective, multicenter, open, and non-comparative study. The study included 203 patients with AH of different severity who received antihypertensive treatment with generic perindopril 4 mg or 8 mg. 188 (92.6 %) patients were included into the main analysis. At the enrollment visit, generic perindopril was replaced with the original drug, Prestarium A 10 mg. The study duration was 3 months. Proportions of patients who reached the target BP were evaluated in the whole patient cohort, monotherapy groups, and generic perindopril 4 mg and 8 mg treatment groups. In the whole cohort, mean age of patients was 60.8±10.1; the cohort contained 39 % of males and 61 % of females. Results. At the Month 1 visit after switching from generic perindopril 4 mg or 8 mg to original Prestarium A 10 mg, mean SBP was reduced by 25 mm Hg and mean DBP was reduced by 12.2 mm Hg (p<0.01). By the end of study, the respective values were already 36.5 mm Hg and 16.6 mm Hg (р<0.01). In the whole cohort, 28.9 % of patients reached the target BP by the Month 1 visit and 70.2 % of patients – by the end of study. This result indicates an additional antihypertensive effect of the original drug. The study has demonstrated capability of the original drug for reducing SBP and DBP when switching patients from generic perindopril both 4 mg and 8 mg. In these groups, 58.2 and 80.4 % of patients, respectively, achieved the target BP (р<0.05 for both groups). Switching from generic perindopril to the original drug resulted in achievement of target BP by 80.6 % and 51.7 % of patients in monotherapy and combination treatment groups, respectively, by the Month 3 visit (р<0.05 for both groups). Conclusion. Switching patients with uncontrolled AH from generic perindopril to the original drug resulted in improvement of BP control and achievement of target BP values in 70.2 % of patients.
  1. Бойцов С. А., Баланова Ю. А., Шальнова С. А., Деев А. Д., Артамонова Г. В., Гатагонова Т. М. и др. Артериальная гипертония среди лиц 25–64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;13 (4):4–14.
  2. Якушин С. С., Филиппов Е. В. Распространенность и особенности ведения больных артериальной гипертонией с различным риском сердечно-сосудистых осложнений (по данным исследования МЕРИДИАН-РО). Медицинский совет. 2013;9:65–9.
  3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC Guidelines for the management of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Sosiety of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357.
  4. Chow СK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013 Sep 4;310 (9):959–68.
  5. Оганов Р. Г., Тимофеева Т. Н., Колтунов И. Е., Константинов В. В., Баланова Ю. А., Капустина А. В. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003–2010 гг. Кардиоваскулярная терапия и профилактика. 2011;10 (1):9–13.
  6. Белоусов Ю. Б., Леонова М. В., Белоусов Д. Ю., Быков А. В., Бекетов А. С. Результаты фармакоэпидемиологического исследования больных артериальной гипертонией в России (ПИФАГОР II). Качественная клиническая практика. 2004;1:17–27.
  7. Тарловская Е. И. Генерики и оригинальные препараты: взгляд практического врача. Русский медицинский журнал. 2008;16 (5):333–7.
  8. Емелина Е. И., Гендлин Г. Е. Престариум А в монотерапии артериальной гипертензии. Лечебное дело. 2011;4:35–42.
Filippov E. V. Efficacy of original perindopril in patients with arterial hypertension: results of the “PRIZNANIE” regional program. Russian Heart Journal. 2015;14 (5):308–315

To access this material please log in or register

Register Authorize
Ru En